CIThe Cigna Group
AI adoption · Q1 2026 earnings call
Health CareScaling
11
extracted from this call
4 / 5
quantified with specifics
Not disclosed
no breakout in this call
AI was a recurring theme across both prepared remarks and Q&A, with incoming CEO Brian Evanko explicitly framing 'AI-enabled health services' as a core pillar of Cigna's forward strategy. Management cited specific operational deployments of Agentic AI in specialty pharmacy, AI-driven risk prediction models in Cigna Healthcare, and AI-assisted biosimilar conversion strategies, with several quantified outcomes disclosed. The call represents a meaningful step toward financializing AI's contribution, particularly the $2,000 per member per year savings figure and the 20-25% reduction in inbound call volumes.
Adopter
See full leaderboard →66/ 100
78
stage: scaling · max spec: 4
55
3 quant outcomes
65
2 scopes
product_embeddedinternal_use
11 AI mentions from this call.
Extracted verbatim from the CI Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T4Prepared remarks· COO· Product-embedded AI
“in Cigna Healthcare, we are using AI-enabled capabilities to improve outcomes through risk prediction models, identifying complex patients earlier and connecting them with our clinical teams. Our predictive high-cost claimants model identifies members with increasing care needs earlier in their clinical journey. This then enables targeted clinical engagements that improve affordability, reduce acute utilization and drive measurable cost savings. To date, for those customers engaged in this model, we see an average of $2,000 per member per year in savings, resulting in the elimination of unnecessary provider and ER visits.”
— Brian Evanko, CI earnings call - T4Prepared remarks· COO· Product-embedded AI
“The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago.”
— Brian Evanko, CI earnings call - T3Prepared remarks· CEO· Product-embedded AI
“This commitment is what spurred us to improve our prior authorization process as outlined in our first customer transparency report, which was released last month. Our goal is to make the process faster and more seamless while ensuring that care is delivered at the right time and right place appropriately and safely. To that end, we have removed hundreds of tests and procedures and services from prior authorization process in the United States, decreasing the volume of medical prior authorizations by about 15%.”
— David Cordani, CI earnings call - T3Prepared remarks· COO· Product-embedded AI
“In Pharmacy Benefit Services, we are utilizing AI to enable better care and service to our customers. This includes leveraging AI in our [ Signature ] model to improve member communication and notifications and help patients make decisions on their care journey and enhancing our capabilities to deliver the lowest out-of-pocket cost for consumers, including with GLP-1s, where we continue to evolve as new oral solutions enter the market and prices decrease.”
— Brian Evanko, CI earnings callSignature - T3Prepared remarks· COO· Product-embedded AI
“Today, we are using Agentic AI, together with our clinical expertise to improve customer and patient experiences. This is enabling us to transform how prescriptions are processed, efficiently schedule prescription orders and proactively identify patients who may need additional service. We do not use AI for clinical decision-making, but rather AI capabilities increase the speed and strengthen the decision quality of our highly experienced clinical teams.”
— Brian Evanko, CI earnings call - T3Q&A· CEO· Product-embedded AIMaybe if I could follow up on Lisa's question and drill down a little bit more on biosimilars and the strength we saw in specialty.
“the team was able to harness effective use of AI to identify the conversion strategies in a highly personalized way, which had high NPS low friction and high continuity for both the patient and the physician. The result of that is the conversion. The result of that is more value delivered, but higher satisfaction and then staying power of the conversion to the biosimilar.”
— David Cordani, CI earnings call - T2Prepared remarks· COO· Product-embedded AI
“I'm humbled and honored to take on the role of CEO in July with a focus on the Cigna Group becoming the clear leader in consumer-focused and AI-enabled health services with an emphasis on clinically complex patients, making care more affordable and more personalized for those we serve.”
— Brian Evanko, CI earnings call - T2Prepared remarks· COO· Product-embedded AI
“By leveraging the combined power of data, advanced analytics and AI, we're able to drive greater customer and client satisfaction through improved affordability of care and greater personalization of services.”
— Brian Evanko, CI earnings call - T2Prepared remarks· COO· Product-embedded AI
“Our results are also enabled by continued investments into harnessing the power of data, advanced analytics and AI, driving new value creation and improved personalization and affordability for our customers.”
— Brian Evanko, CI earnings call - T2Q&A· COO· Internal useI guess, Brian, just in sort of the context of some of the strategic sort of updates that you've been talking about and some of the -- as you sort of transition into the C-suite. Interested if you could maybe also frame it around the 5 growth pillars that have been sort of at the core of the growth strategy for a number of years
“One will be the way we harness data, advanced analytics and AI to drive even more personalized, affordable customer experiences; two, a relentless drive to more affordable types of care.”
— Brian Evanko, CI earnings call - T1Prepared remarks· CEO· Product-embedded AI
“he is committed to further the use of data and AI to drive affordability and personalization, which in turn drives value and sustained growth.”
— David Cordani, CI earnings call
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No explicit AI capex or R&D spend disclosed; management referenced 'continued investments' in data and AI without quantification.
- No AI-specific revenue attribution or ARR disclosed; AI is embedded across existing product lines with no standalone revenue line.
- The $2,000 per member per year savings figure for the high-cost claimant prediction model lacks disclosure of the denominator (number of members engaged), limiting total savings quantification.
- No disclosure of the number of AI models in production, model providers used, or cloud/GPU infrastructure underpinning AI capabilities.
- No analyst directly asked for AI revenue quantification; therefore no explicit deflection to log, but the gap remains material.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.